Table IV.
Association between polymorphisms and the efficacy of pemetrexed-based treatment in advanced NSCLC.
| Genotype | Frequency n (%) | DCR n (%) | ORR n (%) |
|---|---|---|---|
| 2R/2R+2R/3R | 35 (38.9) | 24 (68.6) | 3 (8.6) |
| 3R/3R+3R/4R | 55 (61.1) | 35 (63.6) | 7 (12.7) |
| P-value | 0.631 | 0.541 | |
| Ins6/del6+del6/del6 | 83 (92.2) | 55 (66.3) | 10 (12) |
| Ins6/ins6 | 7 (7.8) | 4 (57.1) | 0 (0) |
| P-value | 0.626 | 0.330 | |
| 2R/2R&6-/6+; 2R/3R&6-/6-; 2R/3R&6-/6+ | 28 (31.1) | 20 (74.1) | 3 (11.1) |
| 2R/2R&6+/6+; 2R/3R&6+/6+ | 7 (7.8) | 4 (57.1) | 0 (0) |
| 3R/4R&6+/6-; 3R/3R&6+/6-; 3R/3R&6-/6- | 55 (61.1) | 34 (62.5) | 7 (12.5) |
| P-value | 0.517 | 0.611 |
DCR, disease control rate; ORR, objective response rate.